): The objectives of the Developmental Research Program are as follows: 1. Publicize the availability of start-up funding for pilot projects in lung cancer translational research. 2. Identify projects that are innovative and have significant potential for reducing lung cancer incidence and mortality or increasing survival. 3. Encourage collaborations among scientists in the SPORE and with scientists outside the SPORE environment. 4. Have the SPORE PI and Co-PI work with investigators to define and articulate translational research goals and steps required to beneficially translate the research into application in humans. 5. Develop specific criteria for selection of projects for funding. 6. Develop a peer-review mechanism to select competing proposals for funding using internal and external reviewers. 7. Provide development funding for projects in the University of Texas SPORE and scientists at other institutions outside the SPORE environment. 8. Develop a mechanism for the SPORE PI and Co-PI to closely monitor and work with the Developmental Projects to help achieve their translational research goals. 9. Develop a program that will be flexible. Developmental projects that show promise will follow one of these courses: a) they will be funded for a second year; b) they will be encouraged to apply for a R01 or other research support; c) they will be elevated to a full SPORE project. Unpromising projects will be terminated. We believe these objectives have been successfully met. This program has funded ten investigators not previously funded by SPORE projects. It has also generated intense interest among non-SPORE investigators that is evidence by the increasing number of projects submitted and approved during the annual solicitations increasing from six to 11 over the last two years. The selection process combining initial internal and subsequent external peer review has worked effectively and efficiently in identifying the best products for funding.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA070907-05S8
Application #
6589741
Study Section
Project Start
2000-09-01
Project End
2003-04-30
Budget Start
Budget End
Support Year
5
Fiscal Year
2002
Total Cost
Indirect Cost
City
Dallas
State
TX
Country
United States
Zip Code
75390
Wang, Jacqueline F; Pu, Xingxiang; Zhang, Xiaoshan et al. (2018) Variants with a low allele frequency detected in genomic DNA affect the accuracy of mutation detection in cell-free DNA by next-generation sequencing. Cancer 124:1061-1069
Rashdan, Sawsan; Minna, John D; Gerber, David E (2018) Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy. Lancet Respir Med 6:472-478
Pierzynski, Jeanne A; Ye, Yuanqing; Lippman, Scott M et al. (2018) Socio-demographic, Clinical, and Genetic Determinants of Quality of Life in Lung Cancer Patients. Sci Rep 8:10640
Akbay, Esra A; Kim, James (2018) Autochthonous murine models for the study of smoker and never-smoker associated lung cancers. Transl Lung Cancer Res 7:464-486
Zhang, Wei; Girard, Luc; Zhang, Yu-An et al. (2018) Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes. Transl Lung Cancer Res 7:32-49
Tan, Xiaochao; Banerjee, Priyam; Liu, Xin et al. (2018) The epithelial-to-mesenchymal transition activator ZEB1 initiates a prometastatic competing endogenous RNA network. J Clin Invest 128:1267-1282
McMillan, Elizabeth A; Ryu, Myung-Jeom; Diep, Caroline H et al. (2018) Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. Cell 173:864-878.e29
Walser, Tonya C; Jing, Zhe; Tran, Linh M et al. (2018) Silencing the Snail-Dependent RNA Splice Regulator ESRP1 Drives Malignant Transformation of Human Pulmonary Epithelial Cells. Cancer Res 78:1986-1999
Skoulidis, Ferdinandos; Goldberg, Michael E; Greenawalt, Danielle M et al. (2018) STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discov 8:822-835
Zhou, Xiaorong; Padanad, Mahesh S; Evers, Bret M et al. (2018) Modulation of Mutant KrasG12D -Driven Lung Tumorigenesis In Vivo by Gain or Loss of PCDH7 Function. Mol Cancer Res :

Showing the most recent 10 out of 1059 publications